相关实验视频
Updated: Jun 18, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
关于帕金森病新型和新兴治疗点的最新情况
Richa Sawant1, Angel Godad2,3
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V M Road, Vile Parle (w), Mumbai, 400056, India.
Metabolic brain disease
|July 27, 2024
概括
本综述探讨了帕金森病 (PD) 的新型治疗点,包括阿贝尔森蛋白和阿佩林蛋白,以修改疾病进展. 它强调了针对神经退行性疾病更有效的治疗方法的多目标策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 帕金森病 (PD) 治疗目前可以控制症状,但不能改变疾病的进展.
- 迫切需要新的治疗策略来修改PD的潜在机制.
研究的目的:
- 审查帕金森病的新兴治疗点.
- 评估新目标的潜力,如阿贝尔森蛋白,拉布菲林-3A,殖民地刺激因子1-受体和阿佩林作为疾病修饰疗法.
- 探索多目标方法在管理PD复杂病理方面的相关性.
主要方法:
- 临床前和临床研究的文献综述.
- 对PD新型治疗点的最新进展和试验结果的分析.
- 对神经退行性疾病的多目标治疗策略的检查.
主要成果:
- 一些新的标,包括阿贝尔森蛋白,拉布菲林-3A,CSF1R和阿佩林,在调节PD进展方面表现有前途.
- 临床前和临床数据表明,这些目标有可能成为疾病修饰剂.
- 多目标方法越来越多地被认为对解决PD复杂病理学的相关性.
结论:
- 新兴的目标为开发帕金森病的疾病修饰疗法提供了新的途径.
- 对这些目标和组合策略的进一步研究对于推进PD治疗至关重要.
- 本综述提供了洞察力,以指导PD和相关疾病的未来研究和临床开发.
相关概念视频
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Parkinson's Disease: Overview
510
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
510
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K

